Personalis PSNL
Personalis FY 2023: revenue $73.5M, up 13%; diluted EPS −$2.25
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-24-022097
- Document
- 10-K
- Exhibit 10.4
- Material contract
- Exhibit 10.5
- Material contract
- Exhibit 10.6
- Material contract
- Exhibit 10.12
- Material contract
- Exhibit 10.13
- Material contract
- Exhibit 10.14
- Material contract
- Exhibit 10.15
- Material contract
Key figures from this report
These are the numbers Personalis reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$73.5M+13% from $65.0M in FY 202210-K income statement, on EDGAR
- Net income−$108.3MAgainst −$113.3M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$2.25Against −$2.48 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$57.0M−36% from $89.1M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$56.3MAgainst −$70.2M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.
- Castle Biosciences CSTL public float $576M, Jun 30, 2025
- Celcuity CELC public float $457M, Jun 30, 2025
- Fortrea Holdings FTRE public float $448M, Jun 30, 2025
- CareDx CDNA public float $1.0B, Jun 30, 2025
- Fulgent Genetics FLGT public float $284M, Jun 30, 2025
